SOLD OUT nationwide ‼️ Similar product here: Suprasorb C Collagen - > https://www.coinmed.mx/products/suprasorb-c-pieza-4-x-8-x-8-cm 🚚 FREE Shipping | GARACOLL ® It is indicated in the complementary treatment of bone and soft tissue infections caused by sensitive bacteria. GARACOLL ® It may also be useful for the prevention of local infections in soft tissues and bone (such as bone graft sites or in the implantation of artificial joints without adhesives).
GARACOLL ® It should not be used as sole therapy if infection is found or suspected. Based on microbiological studies, appropriate antibiotics should be administered systemically.
GARACOLL ® It is a sterile implant that contains gentamicin sulfate, a broad-spectrum antibiotic, and bovine collagen as a carrier substance.
The objective of the implant is to locally provide elevated concentrations of gentamicin at the implant site, resulting in the elimination or prevention of local infections. High local concentrations can persist for several days.
Made in Germany by: Syntacoll GmbH
Reg. NO. 195M96 SSA IV
BOX presentation: 5 implants
Size: 5cm x 5cm x .5cm
Expiration: July 2022
PHARMACOKINETICS AND PHARMACODYNAMICS:
Microbiology: Gentamicin is a bactericidal antibiotic that acts by inhibiting the normal protein synthesis of sensitive µg. It is active against a wide variety of gram-negative and gram-positive bacteria.
Sensitivity (MIC < 1 µg/ml): Citrobacter, Staphylococcus sp .
Moderately sensitive (MIC = 1-4 µg/ml): Pseudomonas aeroginosa, Proteus sp , both indole-positive ( P. vulgaris ) and indole-negative ( P. mirabilis ), Escherichia coli, Enterobacter, Serratia, Streptococcus, Salmonella sp, Shigella, Klebsiella .
Only minimal activity is observed against Streptococcus faecaiis and Diplococcus pneumoniae .
Limited data show susceptibility against some mycoplasma strains. Most anaerobic bacteria ( Clostridium sp, Bacteroides and Diphtheroids ) are resistant. Mycobacteria are also resistant
Bactericidal concentrations of gentamicin are generally 1 to 4 times the minimum inhibitory concentration (MIC). Gentamicin was found to be 8 times more active in vitro at a pH of 7.5 than at 5.5, against various urinary tract pathogens.
Bacterial resistance to gentamicin is due to enzymatic inactivation and generally develops gradually. Cross resistance with other aminoglycosides is possible.
Combining gentamicin with a penicillin or cephalosporin may have a synergistic effect on certain strains of bacteria.
Pharmacokinetic properties: Based on the study of the exudate, high tissue concentrations ranging between 300 and 9,000 µg/ml can be reached in the first 1 to 2 hours. These concentrations exceed the bactericidal concentration of gentamicin several times. Significantly elevated levels may persist in the exudate for 3 to 4 days after surgery. No correlation could be established between the dose (number of implants) and the concentration of the exudate; However, an inverse relationship has been established between the concentration of gentamicin in the exudate and the blood supply at the surgical site. Methods of implantation and location of the implants also significantly affect the release of gentamicin, for example, whether the implant is loose in the wound cavity or attached to bone. All this indicates that the release of gentamicin depends on the rate of collagen resorption.
At the recommended dose, peak serum concentrations are generally around 3 µg/ml in the treatment of bone infections, while higher peak serum concentrations (4 to 5 µg/ml) may be seen for the treatment of soft tissue infections. . However, serum concentrations generally do not reach toxic levels.
Collagen is completely reabsorbed. Absorption time depends on local conditions (see above).